Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Økonomisk Ugebrev Life Science Investor Conference (November 2023)
23 slides from Expres2ion Biotech Holding Ab's conference presentation, Nov 22, 2023
Slide 1: Innovative vaccines for a healthier world
Click to edit Master title style Innovative vaccines for a healthier world 22 November 2023 Hosted by Innovative vaccines for a healthier world ExpreS2ion Biotech Holding AB Org. Nr. 559033-3729
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Agenda
Agenda • Leadership, platform and pipeline • Q3 2023 update • Outlook Innovative vaccines for a healthier world |3
Slide 4: Leadership
Leadership Greater than 200 years deep professional experience to support a pipeline-driven business Management Team Board of Directors Innovative vaccines for a healthier world |4
Slide 5: Unique technology platforms
Unique technology platforms Combines a highly immunogenic antigen with unique presentation technology Particle (VLP) technology ExpreS2™ platform - AdaptVac’s proprietary virus- - Combines S2 cells with like particles (VLP) technology patented expression vectors securely attaches our proteins (add a
Slide 6: Broad clinical stage vaccine pipeline
Broad clinical stage vaccine pipeline Target Pre-clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Partner/Funding COVID-19 ABNCoV2/SARS-CoV-2cVLP ABNCoV2/SARS-CoV-2 cVLP I / II Ph. III finalised Breast Cancer ES2B-C001/HER2-cVLP GMP / tox final sta
Slide 7: Agenda
Agenda • Leadership, platform and pipeline • Q3 2023 update • Outlook Innovative vaccines for a healthier world |7
Slide 8: ABNCoV2 COVID-19 booster vaccine
COVID-19 ABNCoV2 COVID-19 booster vaccine Accelerated development path has confirmed clinical PoC and Phase III-validation 2020-2021 2021-2022 2022-2023 • Phase I • Phase II • Phase III • PREVENT-nCoV consortia of biotech • Sponsored by Bavarian Nordic • Sponsored by Bavarian Nordic and academia par
Slide 9: Q3 update on ABNCoV2 Phase III
COVID-19 Q3 update on ABNCoV2 Phase III • Bavarian Nordic (BN) reported the • Reduced options for raising capital secondary endpoint results for their • Assumptions for TO8 warrant Phase III clinical trial subscription proceeds changed: • Did not successfully meet secondary • SEK 54.5M prospects at
Slide 10: Strategic review
Strategic review Announced in August 2023 Strategic evaluation of ES2B-C001 Identify how to best create value with our unique Initiating a cost technology reduction program platform, expertise and exploratory pipeline projects Innovative vaccines for a healthier world | 10
Slide 11: Outcome of strategic review (I)
Outcome of strategic review (I) Cost reductions Cut over SEK 50 million in Reductions primarily in Cash runway into 2025 costs R&D, personnel and facilities Innovative vaccines for a healthier world | 11
Slide 12: Outcome of strategic review (II)
Outcome of strategic review (II) ES2B-C001 breast cancer vaccine candidate Halted plan for CRO-driven Phase I clinical trial Continuing preparations for advancing into clinical development Preclinical safety studies GMP manufacturing Regulatory alignment Evaluating other development options Investig
Slide 13: Outcome of strategic review (III)
Outcome of strategic review (III) Other activities, including other pipeline assets and platform development Enhancing focus on certain Qualification of various Saying “no” to lower priority exploratory pipeline projects factors driving prioritization activities Timeline leading to value CRO project
Slide 14: Cash balance, 1Q21 – 3Q23 quarterly
FINANCE Cash balance, 1Q21 – 3Q23 quarterly SEK millions 200 175 168 150 150 142 139 125 125 108 111 100 88 83 77 75 72 50 25 0 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 Innovative vaccines for a healthier world | 14
Slide 15: Agenda
Agenda • Leadership, platform and pipeline • Q3 2023 update • Outlook Innovative vaccines for a healthier world | 15
Slide 16: Breast cancer - the most common cancer
BREAST BREAST CANCER CANCER Breast cancer - the most common cancer 1 in 8 women will be diagnosed with invasive breast cancer in her lifetime ~25% are HER2-positive, which is associated with more aggressive tumors and reduced survival. 685,000 deaths worldwide in 2020 due to breast cancer1 Global ma
Slide 17: Current treatments
BREAST CANCER Current treatments • Monoclonal antibodies Existing therapies • Herceptin and Perjeta • $11 billion market • Resistance to monoclonal antibodies may develop • Potential for cardiac toxicity Drawbacks with existing therapies • Repeated administration required: Every 3rd week until remis
Slide 18: Effective when existing treatment isn’t
BREAST CANCER Effective when existing treatment isn’t UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human cancer cells1 Trastuzumab- resistant HER2+ human cancer cells Innovative vaccines for a healthier world | 18
Slide 19: Increased survivability in mice
BREAST CANCER Increased survivability in mice Innovative vaccines for a healthier world | 19
Slide 20: Inhibits tumor development in mice
BREAST CANCER Inhibits tumor development in mice 100 Vehicle ES2B-C001 10 g i.m. ES2B-C0 Tumor-free (%) Vehicle ES2B-C001 10 g i.m. ES2B-C001 10 g i.m.+Mo bleeding administration Vehicle ES2B-C001 10 g i.m. ES2B-C001 10 g i.m.+Montanide bleeding administration 50 N=10 bleeding administration 2.
Slide 21: Oncology Scientific Advisory Board
BREAST CANCER Oncology Scientific Advisory Board Key Opinion Leaders (KOLs) providing clinical advice on our oncology development programme Dr. Giuseppe Curigliano, MD, PhD Dr. Ulrik Lassen, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Professor at University o
Slide 22: Advancing focus pipeline towards key catalysts
Advancing focus pipeline towards key catalysts 2022 2023 2024 2025+ ✓ ✓ ✓ BN Phase II 12-month durability data BN BN Phase II trial BN Phase III trial readout H1 initiation Q3 ✓ Phase III initial readout COVID-19 ABNCoV2 ✓ Phase III secondary readout Phase III milestone related income X Bavarian Nor
Slide 23: Thank you
Thank you investor@expres2ionbio.com Innovative vaccines for a healthier world | 23